Prime Medicine, founded with gene editing tech from the lab of star Harvard biochemist David Liu and backed by blue chip investors, made little secret of its ambition. It laid out plans to use its new gene editing technology across 18 different diseases, listing conditions as disparate as ALS, congenital blindness, and muscular dystrophy.
On Monday, the company vastly scaled back its aims. With cash running short, executives announced Prime will focus its efforts on just three different genetic diseases. At the same, it announced a new cell therapy pact with Bristol Myers Squibb that will immediately bring in $110 million, plus far more in potential milestones. Prime is “identifying partnership opportunities” for the shelved programs.
Click this link for the original source of this article.
Author: Jason Mast
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.
